AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1
Bangalore: AstraZeneca Pharma India Limited has announced that the Company will be discontinuing the manufacturing and marketing of the product Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg (Imdur) from April 1, 2025.
Imdur is currently being indicated for Prophylactic treatment of angina pectoris. Angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle, usually due to coronary artery disease (CAD). It is a symptom of myocardial ischemia (lack of oxygen to the heart).
Read also: AstraZeneca, Harbour BioMed join hands to discover, develop next-generation therapeutic antibodies
AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited is the operating company and covers manufacturing, sales and marketing activities of the company in India.
It is a listed company and is a subsidiary of AstraZeneca Plc, UK.
Read also: AstraZeneca to inject USD 2.5 billion in new RnD centre, biotech pacts, manufacturing in Beijing
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.